538 related articles for article (PubMed ID: 24781258)
1. Automated image analysis of a glomerular injury marker desmin in spontaneously diabetic Torii rats treated with losartan.
Kakimoto T; Okada K; Hirohashi Y; Relator R; Kawai M; Iguchi T; Fujitaka K; Nishio M; Kato T; Fukunari A; Utsumi H
J Endocrinol; 2014 Jul; 222(1):43-51. PubMed ID: 24781258
[TBL] [Abstract][Full Text] [Related]
2. Quantitative analysis of markers of podocyte injury in the rat puromycin aminonucleoside nephropathy model.
Kakimoto T; Okada K; Fujitaka K; Nishio M; Kato T; Fukunari A; Utsumi H
Exp Toxicol Pathol; 2015 Feb; 67(2):171-7. PubMed ID: 25481214
[TBL] [Abstract][Full Text] [Related]
3. Semi-automated quantitative image analysis of podocyte desmin immunoreactivity as a sensitive marker for acute glomerular damage in the rat puromycin aminonucleoside nephrosis (PAN) model.
Herrmann A; Tozzo E; Funk J
Exp Toxicol Pathol; 2012 Jan; 64(1-2):45-9. PubMed ID: 20591637
[TBL] [Abstract][Full Text] [Related]
4. Losartan ameliorates progression of glomerular structural changes in diabetic KKAy mice.
Sasaki M; Uehara S; Ohta H; Taguchi K; Kemi M; Nishikibe M; Matsumoto H
Life Sci; 2004 Jul; 75(7):869-80. PubMed ID: 15183078
[TBL] [Abstract][Full Text] [Related]
5. Effects of angiotensin receptor blocker on phenotypic alterations of podocytes in early diabetic nephropathy.
Dai HY; Zheng M; Tang RN; Ni J; Ma KL; Li Q; Liu BC
Am J Med Sci; 2011 Mar; 341(3):207-14. PubMed ID: 21326079
[TBL] [Abstract][Full Text] [Related]
6. Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes.
Deb DK; Sun T; Wong KE; Zhang Z; Ning G; Zhang Y; Kong J; Shi H; Chang A; Li YC
Kidney Int; 2010 Jun; 77(11):1000-9. PubMed ID: 20182412
[TBL] [Abstract][Full Text] [Related]
7. The effects of angiotensin-II receptor blockers on podocyte damage and glomerular apoptosis in a rat model of experimental streptozotocin-induced diabetic nephropathy.
Tunçdemir M; Oztürk M
Acta Histochem; 2011 Dec; 113(8):826-32. PubMed ID: 21269661
[TBL] [Abstract][Full Text] [Related]
8. Overactive cannabinoid 1 receptor in podocytes drives type 2 diabetic nephropathy.
Jourdan T; Szanda G; Rosenberg AZ; Tam J; Earley BJ; Godlewski G; Cinar R; Liu Z; Liu J; Ju C; Pacher P; Kunos G
Proc Natl Acad Sci U S A; 2014 Dec; 111(50):E5420-8. PubMed ID: 25422468
[TBL] [Abstract][Full Text] [Related]
9. Effect of angiotensin II type 1 receptor blocker on 12-lipoxygenase activity and slit diaphragm protein expression in type 2 diabetic rat glomeruli.
Xu HZ; Wang WN; Zhang YY; Cheng YL; Xu ZG
J Nephrol; 2016 Dec; 29(6):775-782. PubMed ID: 27021232
[TBL] [Abstract][Full Text] [Related]
10. Mesenchymal stem cells ameliorate podocyte injury and proteinuria in a type 1 diabetic nephropathy rat model.
Wang S; Li Y; Zhao J; Zhang J; Huang Y
Biol Blood Marrow Transplant; 2013 Apr; 19(4):538-46. PubMed ID: 23295166
[TBL] [Abstract][Full Text] [Related]
11. Potential role of angiotensin-converting enzyme inhibitors and statins on early podocyte damage in a model of type 2 diabetes mellitus, obesity, and mild hypertension.
Blanco S; Vaquero M; Gómez-Guerrero C; López D; Egido J; Romero R
Am J Hypertens; 2005 Apr; 18(4 Pt 1):557-65. PubMed ID: 15831368
[TBL] [Abstract][Full Text] [Related]
12. Losartan in diabetic nephropathy.
Perico N; Ruggenenti P; Remuzzi G
Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):473-83. PubMed ID: 15225108
[TBL] [Abstract][Full Text] [Related]
13. Effect of losartan on the glomerular protein expression profile of type 2 diabetic KKAy mice.
Fan QL; Yang G; Liu XD; Ma JF; Feng JM; Jiang Y; Wang LN
J Nephrol; 2013; 26(3):517-26. PubMed ID: 22684654
[TBL] [Abstract][Full Text] [Related]
14. ACE-inhibitors but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathy.
Gross ML; El-Shakmak A; Szábó A; Koch A; Kuhlmann A; Münter K; Ritz E; Amann K
Diabetologia; 2003 Jun; 46(6):856-68. PubMed ID: 12802493
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin II type 1 receptor expression is increased via 12-lipoxygenase in high glucose-stimulated glomerular cells and type 2 diabetic glomeruli.
Xu ZG; Miao LN; Cui YC; Jia Y; Yuan H; Wu M
Nephrol Dial Transplant; 2009 Jun; 24(6):1744-52. PubMed ID: 19103735
[TBL] [Abstract][Full Text] [Related]
16. Beneficial effect on podocyte number in experimental diabetic nephropathy resulting from combined atrasentan and RAAS inhibition therapy.
Hudkins KL; Wietecha TA; Steegh F; Alpers CE
Am J Physiol Renal Physiol; 2020 May; 318(5):F1295-F1305. PubMed ID: 32249614
[TBL] [Abstract][Full Text] [Related]
17. Early treatment with olmesartan prevents juxtamedullary glomerular podocyte injury and the onset of microalbuminuria in type 2 diabetic rats.
Sofue T; Kiyomoto H; Kobori H; Urushihara M; Nishijima Y; Kaifu K; Hara T; Matsumoto S; Ichimura A; Ohsaki H; Hitomi H; Kawachi H; Hayden MR; Whaley-Connell A; Sowers JR; Ito S; Kohno M; Nishiyama A
Am J Hypertens; 2012 May; 25(5):604-11. PubMed ID: 22318512
[TBL] [Abstract][Full Text] [Related]
18. Losartan affects glomerular AKT and mTOR phosphorylation in an experimental model of type 1 diabetic nephropathy.
Mavroeidi V; Petrakis I; Stylianou K; Katsarou T; Giannakakis K; Perakis K; Vardaki E; Stratigis S; Ganotakis E; Papavasiliou S; Daphnis E
J Histochem Cytochem; 2013 Jun; 61(6):433-43. PubMed ID: 23456824
[TBL] [Abstract][Full Text] [Related]
19. Effects of candesartan, an angiotensin II type 1 receptor blocker, on diabetic nephropathy in KK/Ta mice.
Liao J; Kobayashi M; Kanamuru Y; Nakamura S; Makita Y; Funabiki K; Horikoshi S; Tomino Y
J Nephrol; 2003; 16(6):841-9. PubMed ID: 14736011
[TBL] [Abstract][Full Text] [Related]
20. Sirolimus damages podocytes in rats with protein overload nephropathy.
Cai Y; Chen Y; Zheng S; Chen B; Yang Y; Xia P
J Nephrol; 2011; 24(3):307-12. PubMed ID: 20954132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
